1 |
ZHENG H C. The molecular mechanisms of chemoresistance in cancers[J]. Oncotarget, 2017, 8(35): 59950-59964.
|
2 |
JIN W, LIAO X D, LV Y P, et al. MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner[J]. Cell Death Dis, 2017, 8(8): e2980.
|
3 |
KUFE D W. Mucins in cancer: function, prognosis and therapy[J]. Nat Rev Cancer, 2009, 9(12): 874-885.
|
4 |
HANISCH F G, MÜLLER S. MUC1: the polymorphic appearance of a human mucin[J]. Glycobiology, 2000, 10(5): 439-449.
|
5 |
KUFE D W. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches[J]. Oncogene, 2013, 32(9): 1073-1081.
|
6 |
NATH S, MUKHERJEE P. MUC1: a multifaceted oncoprotein with a key role in cancer progression[J]. Trends Mol Med, 2014, 20(6): 332-342.
|
7 |
NATH S, DANESHVAR K, ROY L D, et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes[J]. Oncogenesis, 2013, 2: e51.
|
8 |
THULASIRAMAN P, JOHNSON A B. Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells[J]. Int J Oncol, 2016, 49(2): 479-486.
|
9 |
BHATIA R, GAUTAM S K, CANNON A, et al. Cancer-associated mucins: role in immune modulation and metastasis[J]. Cancer Metastasis Rev, 2019, 38(1/2): 223-236.
|
10 |
TAMURA Y, HIGASHI M, KITAMOTO S, et al. MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer[J]. PLoS One, 2012, 7(11): e49251.
|
11 |
WANG H P, JIN S J, LU H L, et al. Expression of survivin, MUC2 and MUC5 in colorectal cancer and their association with clinicopathological characteristics[J]. Oncol Lett, 2017, 14(1): 1011-1016.
|
12 |
RAKHA E A, BOYCE R W G, ABD EL-REHIM D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer [J]. Mod Pathol, 2005, 18(10): 1295-1304.
|
13 |
LV Y P, CANG W, LI Q F, et al. Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer[J]. Oncogenesis, 2019, 8(12): 70.
|
14 |
CASCIO S, FINN OJ. Intra- and extra-cellular events related to altered glycosylation of MUC1 promote chronic inflammation, tumor progression, invasion, and metastasis[J]. Biomolecules, 2016, 6(4): E39.
|
15 |
GROVER P, NATH S, NYE M D, et al. SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line[J]. Oncotarget, 2018, 9(6): 6897-6910.
|
16 |
BOUILLEZ A, RAJABI H, PITRODA S, et al. Inhibition of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung adenocarcinomas[J]. Cancer Res, 2016, 76(6): 1538-1548.
|
17 |
TIEMIN P, FANZHENG M, PENG X, et al. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways[J]. J Hepatol, 2020, 72(4): 761-773.
|
18 |
KUMARI S, KHAN S, GUPTA S C, et al. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer[J]. Oncogenesis, 2018, 7(2): 19.
|